
Medical AI company
Lunit
Seoul-based, KOSDAQ-listed developer of AI for cancer screening (mammography, chest X-ray) and precision oncology tissue analysis.
Company overview
Lunit develops AI software for cancer screening and precision oncology. Its Lunit INSIGHT products analyse mammography, digital breast tomosynthesis and chest X-ray images, while the Lunit SCOPE suite analyses pathology slides, including PD-L1, HER2 and tumour microenvironment assessment for biopharma. The company completed an IPO on KOSDAQ and completed the acquisition of Volpara, whose breast density and risk products appear in Lunit's breast cancer portfolio.
- Headquarters
- Seoul, South Korea
- Founded
- 2013 source
- Company type
- AI Technology Developer
- Status
- Established Company
In its own words: “Transform cancer care with our advanced medical AI software.” source
AI products and platforms
- Lunit INSIGHT MMGAI-powered
AI cancer detection for 2D mammography
Product page ↗ - Lunit INSIGHT DBTAI-powered
AI cancer detection for 3D digital breast tomosynthesis
Product page ↗ - Lunit INSIGHT CXRAI-powered
AI analysis of chest X-rays
Product page ↗ - Lunit SCOPE IOAI-powered
AI tumour microenvironment analysis of pathology slides for immuno-oncology
Product page ↗ - Lunit SCOPE PD-L1 / HER2 / IHC SuiteAI-powered
AI quantification of immunohistochemistry biomarkers on digital pathology slides
Product page ↗
Technology categories
Clinical applications
- breast cancer screening
- chest X-ray reading
- digital pathology biomarker scoring
Relationships
- Partner Summit Therapeutics source
Relationships are shown as stated on the cited page; the other party may not confirm them.
Regulatory information
- FDA clearance for Lunit INSIGHT MMG source
- FDA clearance for Lunit INSIGHT CXR Triage source
- CE mark under EU MDR for Lunit INSIGHT CXR4 and Lunit INSIGHT DBT source
- CE mark for Lunit SCOPE PD-L1 source
As stated by the company or the cited regulator page. Authorisation is specific to a product, version and market; confirm the current status with the company and the regulator. About medical device regulation
Official sources
Last verified 29 October 2026 against the sources above.
Questions about Lunit
Does Medical AI have to explain how it reaches its outputs?
Not always in a technical sense, but transparency about the product is increasingly expected. Many machine learning models cannot give a simple step-by-step reason for each output, so regulators focus on clear information for users: intended use, inputs, how the model was developed and tested, performance, and known limitations.
In the US, one of the criteria for clinical decision support to fall outside device regulation is that a healthcare professional can independently review the basis for its recommendations. FDA has also published transparency principles for machine learning devices with Health Canada and MHRA.
For buyers, a vendor's ability to document how its model works and where it fails is often more useful than heat maps or confidence scores alone.
How is radiology AI different from general diagnostic imaging software?
General diagnostic imaging software stores, displays and manipulates images, for example PACS viewers, 3D reconstruction or measurement tools operated by the user. Radiology AI adds automated analysis that produces its own output, such as a detection, triage flag or quantitative result.
The distinction matters for evaluation:
- Viewing and processing tools are judged mainly on image quality, usability and integration.
- AI analysis tools also need evidence on accuracy, populations studied, failure modes and monitoring.
Both can be regulated medical devices depending on intended use; in the US many image management and processing functions fall under device classifications. Many vendors now combine the two, so ask which functions are AI-based and which are covered by a regulatory authorization.
What are whole-slide images in digital pathology?
A whole-slide image (WSI) is a high-resolution digital scan of an entire glass pathology slide, which can be viewed and navigated on screen at different magnifications, much like a microscope.
WSIs are very large files, often gigabytes per slide, so digital pathology needs fast scanners, substantial storage, network capacity and viewing software. They are the input for pathology AI.
FDA describes a whole slide imaging system as an automated digital slide creation, viewing and management system intended as an aid to the pathologist to review and interpret digital images of surgical pathology slides. Formats vary between scanner vendors, and DICOM has been extended to support whole-slide imaging, which helps interoperability between scanners, archives and AI tools.